

Oricell Closes \$45M Series B1 Financing to Expand Development of Key Products

SHANGHAI, Feb. 28th, 2023 -- Oricell Therapeutics Co., Ltd (“Oricell” or “the Company”), a China-based innovative pharmaceutical company committed to the development of tumor cellular immunotherapeutics, today announced the close of a \$45M Series B1 investment round after the completion of a \$125M Series B fund-raise in July 2022. The round was led by premier global industry investors RTW Investments, LP (“RTW”) and Qatar Investment Authority (“QIA”), with participation from existing investors, including Qiming Venture Partners and C&D Emerging Industry Equity Investment. The new injection of capital will be utilized primarily to support the company’s core product clinical development in the U.S.

Oricell Chairman and CEO Helen Yang said, “We are thrilled with the momentum our team has built over the last several months and look forward to using this funding to further expand our platform and research. This round reflects our investors’ recognition of Oricell’s ongoing growth and the development of our robust pipeline of ground-breaking therapeutics. We look forward to continuing to help improving the lives of patients in need.”

Over the past year, Oricell’s cell therapy pipeline and drug discovery platform have seen tremendous growth. Since the debut of Oricell’s first key product Ori-C101 at the 2021 American Society of Clinical Oncology (“ASCO”) Annual Meeting, the Company has been overcoming many difficulties and made unremitting efforts to achieve all the expected milestones, to attract widespread attention among investors worldwide with its increased presence in the global new drug market during 2022 and into 2023. The Company launched its red-chip restructuring in the fourth quarter of last year in parallel with series B round of financing. Ori-C101 received IND clearance from NMPA in September 2022. At 2022 ASCO annual meeting and European Hematology Association (“EHA”) 2022 congress, Oricell presented the clinical research data of its proprietary CAR-T cell therapy targeting GPRC5D (OriCAR-017) for the treatment of Relapsed/Refractory Multiple Myeloma (“RRMM”). The oral presentation was very well received; subsequently, the product was granted an orphan drug designation by US FDA. Its follow-up data was published in Lancet Haematology on January 31 2023.

With this new funding, the Company is now well-positioned to expand its products to the U.S., specifically OriCAR-017, a GPRC5D CAR-T therapeutic that treats relapsed and refractory multiple myeloma, which is a product currently on the stage of IND enabling both in the US and China.

Roderick Wong, M.D., Managing Partner and Chief Investment Officer of RTW, said “RTW continues to focus on advanced tumor cellular immunotherapeutics. As a long-term investor in the primary and secondary markets, we have been closely following Oricell and have been duly

impressed by its milestone achievements over the past year. Today, we feel honored to have established a partnership with the company through the Series B1 financing. With our years of experience working in the U.S. market, we look forward to empowering Oricell and its team as they continue to provide cancer patients across the world with better therapies and create more value for the community.”

About RTW Investment

Headquartered in New York, with offices in Shanghai and London, RTW Investments, LP is a global life sciences investment and innovation firm that focuses on identifying transformational and disruptive innovations across the biopharmaceutical and medical technologies sectors. As a leading partner of industry and academia, RTW combines deep scientific expertise with a solution-oriented investment approach to advance emerging medical therapies by building and supporting the companies and/or academics developing them. For further information about RTW, please visit www.rtwfunds.com

About Qatar Investment Authority

Qatar Investment Authority (“QIA”) is the sovereign wealth fund of the State of Qatar. QIA was founded in 2005 to invest and manage the state reserve funds. QIA is among the largest and most active sovereign wealth funds globally. QIA invests across a wide range of asset classes and regions as well as in partnership with leading institutions around the world to build a global and diversified investment portfolio with a long-term perspective that can deliver sustainable returns and contribute to the prosperity of the State of Qatar.

Media Contact: media@qia.qa

About Qiming Venture Partners

Founded in 2006, Qiming Venture Partners is a leading China venture capital firm with offices in Shanghai, Beijing, Suzhou, Hong Kong, Seattle, Boston and the San Francisco Bay Area. Currently, Qiming Venture Partners manages eleven US Dollar funds and seven RMB funds with \$9.4 billion in capital raised. Since our establishment, we have invested in outstanding companies in the Technology and Consumer (T&C) and Healthcare industries at the early and growth stages.

About C&D Emerging Industry Equity Investment

Xiamen C&D Emerging Industry Equity Investment Co., Ltd is a professional equity asset management company affiliated to Xiamen C&D Corporation Limited, focusing on new economy sectors including healthcare, advanced manufacturing and innovative consumption.

The subsidiary manages a fund of RMB18 billion to help more emerging enterprises flourish.

About Oricell Therapeutics

Oricell Therapeutics was founded in 2015 as an innovative biopharmaceutical company in China. It is committed to developing tumor cellular immunotherapeutics through its own innovative technology platforms. Oricell has applied for over 100 invention patents (including 6 PCT), with 10 already granted.

Oricell Therapeutics' mission is to develop affordable drugs for unmet clinical needs worldwide. It has built several proprietary technology platforms based on tumor cell immunotherapy, including Ori® Ab and Ori® CAR. Oricell Therapeutics has made several achievements to overcome challenges to treat solid tumors including among others antibody engineering construction technology, tumor immune microenvironment regulation, T cell infiltration and killing ability.

With over 10 cellular projects in its pipeline, Oricell Therapeutics is well positioned to develop novel cell therapies to treat liquid and solid tumors. Oricell focuses on indications with a wide range of therapeutic needs, including liver, ovarian, gastric, cervical and non-small cell lung cancer, as well as multiple myeloma. With the corporate goal of becoming an innovation-driven global leader in the creation of new tumor immunotherapeutics, Oricell Therapeutics has established an international product development and operations management team, GMP-compliant manufacturing facilities and quality testing and management systems. Oricell Therapeutics is continuing to explore and develop therapeutically effective, well differentiated and affordable drugs through its own innovative technology platforms. The company seeks to create new opportunities for the development of innovative China-made drugs. Oricell raised over \$120 million USD in series B financing in July 2022.

原启生物宣布完成 4500 万美元 B1 轮融资，加速推进核心产品全球开发进程

中国上海，2023 年 2 月 28 日一家立足中国、致力于创新肿瘤免疫治疗药物开发公司——原启生物科技（上海）有限责任公司（下称“原启生物”）宣布，继在 2022 年 7 月完成 1.25 亿美元 B 轮融资后，近日完成了 4500 万美元的 B1 轮融资，将主要用于支持其核心产品在国际市场的临床开发。本轮融资由全球知名产业投资者 RTW Investments 与 QIA（Qatar Investment Authority 卡塔尔投资局）联合领投，现有股东启明创投、建发新兴投资等继续投资。

原启生物董事长兼首席执行官杨焕凤女士表示，“非常感谢 RTW 和 QIA 的认可，也非常感谢老股东对公司的支持。本轮融资顺利完成，体现了各位投资人对原启生物近年来在核心产品开发、技术平台建设等方面成绩的肯定，对公司长远未来的持续看好。投资人的坚定支持给原启团队带来了巨大的鼓舞。”

历时八年积累和沉淀，原启生物自主创新 CAR-T 技术平台及其核心产品得到了更多的临床验证。继公司的第一个核心产品 Ori-C101 在 2021 年 ASCO（American Society of Clinical Oncology 美国临床肿瘤学会）年会上初次亮相国际舞台后，公司 2022 年和 2023 年在全球新药市场的曝光度不断提高，持续吸引了全球投资者的广泛关注。在 2022 年疫情管控封城的情况下，团队克服重重艰难、不懈努力，达成了所有预期的里程碑。

除 Ori-C101 获得中国 NMPA 批准开展注册临床试验外，2022 年 6 月公司在 2022 年 ASCO 年会以及 2022 年 EHA（European Hematology Association 欧洲血液学协会）年会就其 OriCAR-017 疗法进行了口头报告；同年 10 月 OriCAR-017 获得美国 FDA 授予的“ODD”（孤儿药资格认定）；2023 年 1 月底，OriCAR-017 的临床随访数据也获得国际顶尖临床医学期刊 Lancet Haematology《柳叶刀血液学》发布。原启生物自启动 B 轮融资时，同步展开红筹重组工作，目标是将原启生物发展成为一个具有技术和产品领先优势的国际化创新药企。

杨焕凤进一步表示：“令我感到非常幸运并欣慰的是，B1 轮的新增投资人 RTW 和 QIA 的加入将会给我们带来更多的国际化资源和帮助。在今后的发展过程中，原启团队将始终秉承开发具有全球临床价值的创新疗法的初心，加快中美优势产品的注册申报和临床开发工作，加快构建中美两

地创新产品开发能力，优化产品生产及供应链运营管理流程、降本增效，用卓越成果回报股东信赖与支持，用优质产品满足与回报临床医生与患者的需求。”

联合领投方 RTW 主管合伙人 Roderick Wong, M.D., 表示：“RTW 一直关注肿瘤免疫细胞治疗领域的前沿治疗方案。作为一二级市场的长期投资者，我们一直关注原启的发展，有幸见证了公司在 2022 年所取得的里程碑。此次非常荣幸可以在 B1 轮融资与原启生物合作，通过我们在美国多年积累的资源为公司赋能，未来我们将与公司团队携手，为全球更多的肿瘤患者提供更好的治疗选择，创造更大的社会价值。”

关于 RTW

RTW Investments, LP 总部位于纽约，在上海和伦敦设有办事处，是一家专注于生物制药和医疗技术领域的转化和颠覆性创新技术的全球生命科学投资和创新公司。作为工业界和学术界的领先合作伙伴，RTW 将深厚的科学专业知识与以解决方案为导向的投资方法相结合，通过建立、支持并赋能的公司或学术机构来推进新兴医学疗法。有关 RTW 的更多信息，请访问 www.rtwfunds.com。

关于 QIA

卡塔尔投资局（“QIA”）是卡塔尔国的主权财富基金。QIA 于 2005 年成立，负责投资和管理国家储备基金。QIA 是全球最大、最活跃的主权财富基金之一。QIA 投资于多种资产类别和区域，并与世界各地的领先机构结成伙伴关系，以建立一个具有长期前景的全球多元化投资组合，从而实现可持续回报并为卡塔尔国的繁荣做出贡献。

媒体联系：media@qia.qa

关于启明创投

启明创投成立于 2006 年，先后在上海、北京、苏州、香港，西雅图、波士顿和旧金山湾区设立办公室。目前，启明创投旗下管理 11 只美元基金，7 只人民币基金，已募管理资产总额达到 94 亿美元。自成立至今，专注于投资科技及消费（Technology and Consumer, T&C）、医疗健康（Healthcare）等行业早期和成长期的优秀企业。

关于建发新兴投资

建发新兴投资成立于 2014 年，是“世界 500 强”厦门建发集团旗下专业的权益类资产管理机构。公司以“开拓新价值，帮助更多新兴企业实现更好的发展”为使命，重点聚焦医疗健康、先进制造、TMT/消费等新经济领域。

关于原启生物

原启生物成立于 2015 年，是一家致力于自主创新技术平台开发肿瘤细胞免疫治疗产品的中国创新药企。截至当前，公司已经申请专利百余项（包括六项 PCT），获得授权 10 项。

原启生物以为全球未被满足的临床需求开发效价可及的药物为使命，自主创新构建了基于肿瘤细胞免疫治疗的 Ori®Ab、Ori®CAR 等多个专利技术平台，并从抗体的筛选和优化、肿瘤免疫微环境改善、T 细胞高效浸润与持久杀伤能力等方面着手突破了治疗实体肿瘤的疗效瓶颈。公司开发的首个靶向 GPC-3 的 CAR-T 产品的探索性临床研究数据积极，亮相 2021 年 ASCO 年会，于 2022 年 9 月获得了 NMPA 的 IND 临床试验批件。靶向 GPRC5D 治疗复发难治多发性骨髓瘤的产品 OriCAR-017 临床研究数据获 2022 年 ASCO 年会和 2022 年 EHA 年会接收进行口头报告，随后该产品于 2022 年 10 月获得美国 FDA 孤儿药资格认定，随访数据于 2023 年 1 月在国际临床医学期刊 Lancet Haematology《柳叶刀血液学》发布。原启生物首个自主研发的免疫检查点 (PD-L1/4-1BB) 双特异性抗体药物 YN051 (ATG101) 以首付款+里程碑 1.42 亿美金的金额授权给德琪医药 (B.6996) 继续开发，该项目已在澳大利亚、美国和中国三地的开展注册临床试验 I 期。

目前，原启生物已有超过 10 个针对肿瘤治疗的细胞药物管线。重点关注包括肝癌、胃癌、胰腺癌、胆管癌、卵巢癌、非小细胞肺癌、多发性骨髓瘤等具有广泛的治疗需求适应症。原启生物始终秉持着“成为创新驱动的全球领先肿瘤免疫治疗新药的创制者”的企业愿景，组建了国际化产品开发、生产、质量管理、临床开发团队，建设了符合 GMP 规范的生产设施和质量检测及管理体系，将不断通过自主创新的技术平台，探索开发疗效好、差异化、成本可及的创新型肿瘤的细胞免疫治疗药物，力争在“创新药、中国造”的发展机遇中不断开立新局。

2022 年 7 月，原启生物完成总金额超过 1.2 亿美元的 B 轮融资。